STOCK TITAN

Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Celsion Corporation (NASDAQ: CLSN) announced that Dr. Khursheed Anwer, Chief Science Officer, will present virtually at the International Vaccines Congress on October 18, 2021, at 7:30 a.m. ET. His presentation, titled “Immunogenicity of DNA Vaccines based on Multicistronic Vectors and Synthetic DNA Delivery Systems,” can be accessed via the company’s website. Celsion’s PLACCINE platform, which supports next-generation DNA vaccines, is under provisional patent and aims to address various infectious diseases efficiently.

Positive
  • Celsion's PLACCINE platform is under provisional patent, indicating potential for innovation.
  • Dr. Anwer's presentation at a significant conference could enhance visibility for Celsion's research.
Negative
  • No specific financial metrics or clinical results were disclosed, leaving investors without concrete data.

Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation Monday, October 18 at 7:30 a.m. Eastern Time

LAWRENCEVILLE, N.J., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that a time of Monday, October 18, 2021 at 7:30 a.m. Eastern time has been set for Khursheed Anwer, Ph.D., executive vice president and chief science officer, to deliver his presentation at the International Vaccines Congress. A link to Dr. Anwer’s presentation, titled “Immunogenicity of DNA Vaccines based on Multicistronic Vectors and Synthetic DNA Delivery Systems,” will be available on Celsion’s website at that time and can be viewed here.

The virtual conference is being held October 18-19, 2021.

About the PLACCINE Platform

PLACCINE is Celsion’s proprietary plasmid and DNA delivery technology and the subject of a provisional patent application that covers a broad range of next-generation DNA vaccines. An adaptation of the Company’s TheraPlas technology, PLACCINE is a DNA vaccine technology platform characterized by a single plasmid DNA with multiple coding regions. The plasmid vector is designed to express multiple pathogen antigens along with a potent immune modifier. It is delivered via a synthetic delivery system and has the potential to be easily modified to create vaccines against a multitude of infectious diseases, addressing:

  • Viral Mutations: PLACCINE may offer broad-spectrum and mutational resistance (variants) by targeting multiple antigens on a single plasmid vector.
  • Enhanced Efficacy: The potent immune modifiers such as cytokines and chemokines may improve humoral and cellular responses to viral antigens and can be incorporated in the plasmid.
  • Durable Efficacy: PLACCINE delivers a DNA plasmid-based antigen that can result in durable antigen exposure and a robust vaccine response to viral antigens.
  • Storage & Distribution: PLACCINE allows for stability that is compatible with manageable vaccine storage and distribution.
  • Dosing & Administration: PLACCINE is a synthetic delivery system that should require a simple injection that does not require viruses or special equipment to deliver its payload.

About Celsion Corporation

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies, DNA-based therapies and directed chemotherapies through clinical trials and eventual commercialization. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit www.celsion.com.

Forward-looking Statements

Forward-looking statements in this news release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding the platform having the potential to provide broad protection against coronavirus disease 2019 (COVID-19), and possible future mutations of SARS-CoV-2 or other coronaviruses. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of the Company’s platform to provide broad protection against COVID-19, and possible future mutations of SARS-CoV-2 or other coronaviruses, the issuance of a patent to the Company for use of its technology platform for treating or preventing infection with the SARS-CoV-2 virus that causes COVID-19, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in the Celsion's periodic filings with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

CONTACTS:

Celsion Corporation
Jeffrey W. Church
Executive Vice President and CFO
609-482-2455
jchurch@celsion.com

LHA Investor Relations
Kim Sutton Golodetz 212-838-3777
kgolodetz@lhai.com

# # #


FAQ

When is Dr. Khursheed Anwer's presentation at the International Vaccines Congress?

Dr. Khursheed Anwer's presentation is scheduled for October 18, 2021, at 7:30 a.m. Eastern Time.

What is the focus of Celsion's PLACCINE platform?

Celsion's PLACCINE platform is focused on developing next-generation DNA vaccines using a proprietary plasmid technology.

Where can I view Dr. Anwer's presentation?

Dr. Anwer's presentation can be viewed on Celsion's official website during the scheduled time.

What is the significance of the PLACCINE platform?

The PLACCINE platform may offer broad-spectrum protection against viral mutations and enhance vaccine efficacy.

What is the ticker symbol for Celsion Corporation?

The ticker symbol for Celsion Corporation is CLSN.

CLSN

:CLSN

CLSN Rankings

CLSN Latest News

CLSN Stock Data

13.91M